Evidence map›Paper›PMID 36261449›Full record

ArticleScientific reports2022

Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.

Deniz Ozberk, Alison Haywood, Heidi G Sutherland, Chieh Yu, Cassie L Albury, Mathew Zunk, Rani George, Phillip Good, Lyn R Griffiths, Janet Hardy and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Deniz OzberkSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia.
Alison HaywoodSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia. a.haywood@griffith.edu.au.
Heidi G SutherlandStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Chieh YuStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Cassie L AlburyStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Mathew ZunkSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia.
Rani GeorgeSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia.
Phillip GoodMater Research Institute, The University of Queensland, Brisbane, Australia.
Lyn R GriffithsStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Janet HardyMater Research Institute, The University of Queensland, Brisbane, Australia.
Larisa M HauptStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, Brisbane, QLD, 4059, Australia. larisa.haupt@qut.edu.au.
Queensland University of Technology · AUGriffith University · AUMater Research · AUSt Vincent’s Private Hospital Brisbane · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opioids are the therapeutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however the unpredictable inter-individual response to opioid therapy remains a challenge for clinicians. While studies are few, the KCNJ6 gene is a promising target for investigating genetic factors that contribute to pain and analgesia response. This is the first association study on polymorphisms in KCNJ6 and response to methadone for pain management in advanced cancer. Fifty-four adult patients with advanced cancer were recruited across two study sites in a prospective, open label, dose individualisation study. Significant associations have been previously shown for rs2070995 and opioid response in opioid substitution therapy for heroin addiction and studies in chronic pain, with mixed results seen in postoperative pain. In this study, no associations were shown for rs2070995 and methadone dose or pain score, consistent with other studies conducted in patients receiving opioids for pain in advanced cancer. There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians.

Indexed as

Chronic PainNeoplasmsAdultAnalgesics, OpioidDeathG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHumansMethadonePain ManagementProspective StudiesAnalgesics, OpioidG Protein-Coupled Inwardly-Rectifying Potassium ChannelsKCNJ6 protein, humanMethadone

Identifiers

PMID36261449
PMCPMC9582209
OpenAlexW4306784354

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.